The efficacy , safety , and tolerability of the combination of simeprevir , a one-pill , once-daily , oral HCV NS@/@A protease inhibitor versus placebo , plus peginterferon alfa @a or @b plus ribavirin was assessed in treatment-naive patients with HCV genotype @ infection .